Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Casein Glycomacropeptide in Healthy Subjects

NCT02832700

Gastrointestinal Disease

COMPLETED NA

Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)

NCT00194922

Irritable Bowel Syndrome (IBS)

COMPLETED PHASE2

Nutrition to Relieve IBS Symptoms by Targeting the Microbiota

NCT04790422

Irritable Bowel Syndrome

COMPLETED NA

GutMe!: IBS and Collagen Protein Powder an Interventional Study

NCT04245254

Irritable Bowel Syndrome Irritable Bowel Irrit

COMPLETED NA

Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome

NCT05819281

Irritable Bowel Syndrome

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In vitro assays show that GMP strongly promotes the growth of beneficial bacteria including Bifidobacterium breve, B. bifidum, B. infantis and Lactococcus lactis. GMP also binds to pathogenic bacteria and prevents their adhesion to intestinal cells, which could prevent enteric infection. GMP also modulates the inflammatory response of key gut immune cells called macrophages. However, the extent to which daily consumption of GMP alters the gut microbiome, metabolome and protein profile of subjects with IBS remains unknown.

This study will investigate how daily GMP consumption can alter the gut microbiome, metabolome and protein profile of subjects with IBS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

single group assignment

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Casein glycomacropeptide (CGMP)

The subjects will receive a daily oral intake of CGMP-protein-shake for 3 weeks with a 1 week wash-in and a 3 week wash-out.

Intervention: Dietary Supplement: Casein glycomacropeptide (CGMP)

Group Type OTHER

Casein glycomacropeptide (CGMP)

Intervention Type DIETARY_SUPPLEMENT

Casein glycomacropeptide (CGMP) supplementation for 3 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Casein glycomacropeptide (CGMP)

Casein glycomacropeptide (CGMP) supplementation for 3 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fluent in English
* IBS diagnosis with Rome IV criteria
* People who have a primary care provider

Exclusion Criteria

* Lactose or milk protein intolerance
* Any known other gastrointestinal disease or disorder beyond IBS, or major gastrointestinal surgery
* Habitual use of laxatives or antacids
* Pregnant or nursing.
* Use of pre or probiotics within one month prior to the study
* Use of antibiotics within one month prior to the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No